US and EU Osteoporosis Drugs Market Size & Opportunities Analysis - Growth Strategies, Competitiveness, and Forecasts (2025 - 2032)

The U.S. osteoporosis drugs market was valued at USD 10.1 billion in 2024 and is projected to grow at a CAGR of 4.8%, reaching USD 14.5 billion by 2032. This growth is attributed to the strong presence of industry giants, advanced healthcare infrastructure, high government investment in healthcare, and increasing awareness about osteoporosis. The U.S. government and healthcare organizations are heavily focused on educating the public, particularly women, about bone health, further supporting market expansion.

Meanwhile, the European Union osteoporosis drugs market is also expanding rapidly, driven by the aging population, urbanization, and growing awareness about osteoporosis care. The increase in osteoporosis prevalence, coupled with the aging demographic and rising healthcare expenditures, is fueling the demand for osteoporosis medications. Both regions face a significant burden from the disease, which further contributes to the market's growth as both populations prioritize preventative and treatment solutions.

Key Insights

The bisphosphonates category dominated the market in 2024, holding 35% of the share. These drugs are effective in reducing fracture risk, particularly in post-menopausal women, which is a major factor contributing to their sustained demand. RANK Ligand inhibitors are the fastest-growing segment, projected to grow at a CAGR of 5.4%. This growth is due to the increasing approval of biosimilars and their effectiveness when used in combination with other treatments to enhance overall bone density and reduce bone resorption.

In the U.S., approximately 2 million osteoporosis-related fractures occur annually, with an associated cost of around USD 19 billion. The condition affects about 10 million people, including 8 million women, highlighting the high prevalence and the need for effective treatments. The EU faces a similar challenge, with 30 million people currently affected by osteoporosis, and the incidence of osteoporotic fractures is expected to rise sharply in the coming years. The aging population, combined with lifestyle factors, significantly contributes to the rise in osteoporosis cases.

Oral & spray medications represented the largest market share in 2024, holding 55% due to their non-invasive nature, ease of use, and cost-effectiveness. These medications are commonly recommended for long-term bone health management. Injectable osteoporosis treatments, such as biologics, are expected to grow at the highest rate of 4.9% CAGR, as these therapies provide higher efficacy, especially in patients with severe osteoporosis or those who experience side effects from oral medications.

In the U.S., the population aged 65 and above is rapidly growing, with projections suggesting that by 2040, 1 in 5 Americans will be in this age group. This demographic shift is a primary driver of osteoporosis drug demand, as older adults are more susceptible to bone density loss. Similarly, the EU's aging population, expected to comprise 29% of the total population by 2060, will continue to drive the demand for osteoporosis treatments. Osteoporotic fractures are projected to rise in parallel, creating significant pressure on healthcare systems.

The osteoporosis drugs market is consolidated, with major players such as Amgen, Eli Lilly, Pfizer, Merck, and Novartis holding significant shares. These companies invest heavily in research and development, navigating stringent regulatory processes, and clinical trials to introduce effective osteoporosis drugs. Emerging players, particularly those developing biosimilars, are increasingly entering the market, with companies like Aurobindo Pharma and Celltrion making significant strides in advancing RANK ligand inhibitors and other treatment options.

In the U.S., drug development and approval are influenced by regulatory bodies such as the FDA, which oversee the approval process for osteoporosis drugs. Similarly, in Europe, the European Medicines Agency (EMA) plays a crucial role in drug approvals, particularly for biologics and biosimilars. These regulatory frameworks ensure that only safe and effective treatments reach the market, fostering trust in the therapies available to patients.